
News
June 10, 2021
Allysta Pharmaceuticals, Inc. Announces Start of Phase 1 Clinical Trial of ALY688-SR, a Novel First-in-Class Peptide that Targets Adiponectin Signaling
December 15, 2020
Allysta Pharmaceuticals, Inc. Announces Positive Preclinical Data in a NASH Model Demonstrating its Adiponectin Analogue ALY688 Reduces Liver Fat, Inflammation, and Fibrosis
December 1, 2020
Allysta Pharmaceuticals, Inc. Announces Positive Results from its Phase 1/2a Clinical Trial of ALY688 Ophthalmic Solution in Dry Eye Disease
January 8, 2020
Allysta Pharmaceuticals, Inc. Doses First Patient with ALY688 Ophthalmic Solution in Phase 1/2a Dry Eye Study
December 18, 2019
Allysta Pharmaceuticals, Inc. Raises Additional $5 Million in Series A Financing to Advance Novel Therapeutic for NASH
April 22, 2019
Allysta Pharmaceuticals, Inc. to Present New Results on ALY688 at the Annual Meeting of ARVO
April 16, 2019
Allysta Pharmaceuticals, Inc. Raises $15 Million in
Series A Financing to Advance Novel Therapeutic for Dry Eye Disease
April 4, 2018
Allysta Pharmaceuticals, Inc. Doses First Patient in Phase 2A Study in Glaucoma
May 13, 2017
Data on Allysta Pharmaceuticals’ Lead Compound, ADP355, Presented at the Annual Meeting of ARVO in Baltimore MD
Poster presented by Prof KC Yoon, Chairman, Dept Ophthalmology, Chonnam University, Korea
February 22, 2017
Allysta Pharmaceuticals, Inc. to present at the QB3 – 2017 Life Science Pitch Summit
February 22, 2017
Allysta Pharmaceuticals, Inc. to present at the National Investment Banking Association Conference
December 12, 2016
Allysta Pharmaceuticals, Inc. to present at the Ninth Annual Biotech Showcase Conference in San Francisco